UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
Clinical trial NCT01988662 · COMPLETED
Trial details
- NCT number
- NCT01988662
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2014-04-01
- Primary completion
- 2015-09-01
- Enrollment
- 205
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.